Microenvironment-A role in tumour progression and prognosis

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 9, 2013, Pages 2096-2099

  Krishna Muppalla, Jaya Nagendra ^a   Muddana, Keerthi ^a   Reddy Dorankula, Shyam Prasad ^a   Rao Thokala, Madhusudan ^a   Prakash Pasupula, Ajay ^a  

^a Kamineni Institute of Dental Sciences ^*  (India)

Author keywords

Cancer stem cells; Cytokines; Extra Cellular Matrix; Tumour associated fibroblasts

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIN; BRYOSTATIN; CHEMOKINE RECEPTOR CXCR4; CILENGITIDE; EPIDERMAL GROWTH FACTOR; ETARACIZUMAB; FIBROBLAST GROWTH FACTOR; FIBROMODULIN; GELATINASE B; GIRENTUXIMAB; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE B; SCATTER FACTOR; SEPRASE; SIBROTUZUMAB; SMALL INTERFERING RNA; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VOLOCIXIMAB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTATION; CANCER CELL; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CONNECTIVE TISSUE CELL; CYTOKINE RELEASE; DENDRITIC CELL; DRUG RESEARCH; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; FLUID BALANCE; GLIOMA; HUMAN; HYPOXIA; INFLAMMATORY CELL; NONHUMAN; PHENOTYPE; REVIEW; STROMA; TUMOR ASSOCIATED FIBROBLAST; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84883854581     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/6619.3419     Document Type: Review

References (38)

1. Hendrik Ungefroren, Susanne Sebens, Daniel Seidl, Hendrik Lehnert, Ralf Hass. Interaction of tumour cells with the microenvironment. Cell Communication and Signaling. 2011;9:1-8
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-45.
3. Eltzschig HK., Carmeliet, P Hypoxia and inflammation. N. Engl. J. Med. 2011; 7:656-65.
4. Flavell RA, Sanjabis, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGF beta. Nat Rev Immunol. 2010; 10 (8):554-57.
5. Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 2012; 1:44-54.
6. Mihaela Lorger. Tumour Microenvironment in the Brain. Cancers. 2012; 4:218-43.
7. Tredan, O, Carlos M, Galimarini, Krupa Patel, Lan F. Drug resistance and the solid tumour microenvironment. J Natl Cancer Inst. 2007; 99(19):1441-54.
8. Farmer P, Bonnefoi H, Anderle P, Cameron D, Aguet M, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 15(1): 68-74.
9. Tonya C. Walser, Jane Yanagawa, Edward Garon, Jay M. Lee, and Steven M. Dubinett. Tumour Microenvironment. Current Clinical Oncology. 2010; 28-69.
10. Calorini L, Bianchini F: Environmental control of invasiveness and metastatic dissemination of tumour cells: the role of tumour cell-host cell interactions. Cell Commun Signal. 2010;8:24.
11. Rigo A, Gottardi M, Zamò A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F: Macrophages may promote cancer growth via a GM-CSF/ HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer. 2010; 9:273.
12. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol. 2005;17:163-69.
13. Pasquet, M, Golzio M, Mery, E, Rafii, A, Benabbou, N. Mirshahi, P.; et al. Hospicells (ascites-derived stromal cells) promote tumourigenicity and angiogenesis. Int. J. Cancer. 2010, 9, 2090-2101.
14. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;7347: 298-307
15. Magali Castells, Benoît Thibault, Jean-Pierre Delord, Bettina Couderc. Implication of Tumour Microenvironment in Chemoresistance: Tumour-Associated Stromal CellsProtect Tumour Cells from Cell Death. Int. J. Mol. Sci. 2012; 13, 9545-71.
16. Verona, E. V, Elkahloun AG, Yang J, Bandyopadhyay A, Yeh IT, Sun LZ. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res. 2007; 67(12):5737-46.
17. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedes F, Delaunay T, Naeem R., et al., Stromal fibroblasts present in invasive human breast carcinomas promote tumour growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121: 335-48.
18. Xu Y, Tabe Y, Jin L, Watt J, McQueen T, Ohsaka A, Andreeff, M.;et al. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGFbeta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br. J. Haematol. 2008; 2:192-201.
19. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC. Mertens, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011; 6:2076-88.
20. Kristian Pietras, Jessica Pahler, Gabriele Bergers, Douglas Hanahan. Functions of paracrine PDGF signaling in the proangiogenic tumour stroma revealed by pharmacological targeting. PLoS Med. 2008; 5(1): 19.
21. Margolin DA, Silinsky J, Grimes C, Spencer N, Aycock, M.; Green, H.;et al. Lymph node stromal cells enhance drug-resistant colon cancer cell tumour formation through SDF-1alpha/CXCR4 paracrine signaling. Neoplasia. 2011; 9:874-86.
22. Brabek J, Mierke CT, Rosel D, Vesely P and Fabry B. The role of the tissue microenvironment in the regulation of cancer cell motility and invasion. Cell Commun Signal. 2010; 8: 22.
23. Ungefroren H, Sebens S, Seidl D, Lehnert H, Hass R. Interaction of tumour cells with the microenvironment. Cell Commun Signal. 2011; 9:18.
24. Levental, K. R, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT., et al., Matrix crosslinking forces tumour progression by enhancing integrin signaling. Cell. 2009; 139(5): 891-906.
25. Fukumura, D. and R.K. Jain, Tumour microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res. 2007; 74(2-3): 72-84.
26. Leight JL, Wozniak MA, Chen S, Lynch ML and Chen CS. Matrix rigidity regulates a switch between TGF-beta1-induced apoptosis and epithelial-mesenchymal transition. Mol Biol Cell. 2012; 23: 781-91.
27. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat 2011; 3:191-201.
28. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006; 3:177-85.
29. Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK. Hypoxia-induced autophagy promotes tumour cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012; 72(7):1773-83.
30. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat. Rev. Cancer 2009; 9: 665-74.
31. Roodhart, JM, Daenen LG, Stigter EC, Prins HJ, Gerrits J, Houthuijzen JM, et al. Mesenchymal stemncells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011; 3:370-83.
32. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8: 579-91.
33. Bauerle T, Komljenovic D, Merz M, Berger MR, Goodman SL, Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer. 2011; 128:2453-62.
34. Reardon DA, Akabani G, Coleman RE, Allan H, Friedman, Henry S Friedman, James E Herndon II., et al., Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002; 20:1389-97.
35. Sauer S, Erba PA, Petrini M, Menrad A, Giorannoni L, Grana C, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumours enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009; 113: 2265-74.
36. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009; 2: 36.
37. Bingham CO III, Smugar SS, Wang H, Tershakove AM. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo. Rheumatology. 2009; 48:1122-27.
38. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP., et al., A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002; 50: 857-60.